ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Good point Silvr,

The following is for the benefit of other readers:

This is what some will be comparing it to

For the fourth quarter 2016:
• Net revenues of $38.2 million, an increase of 112% as compared to the same
period in 2015
• GAAP net loss of $1.1 million, including $6.7 million non-cash impairment charge
for a non-core asset
• Diluted GAAP loss per share of $0.09, including impact of non-cash impairment
charge of $0.36, net of tax
• Adjusted non-GAAP EBITDA of $17.9 million
• Adjusted non-GAAP net income per diluted share of $0.84 (previous methodology)

For the full year ended December 31, 2016:
• Record net revenues of $128.6 million, an increase of 69% versus the prior year
• GAAP net income of $3.9 million, including $6.7 million non-cash impairment
charge for a non-core asset
• Diluted GAAP earnings per share of $0.34, including impact of
non-cash impairment charge of $0.36, net of tax
• Adjusted non-GAAP EBITDA of $61.1 million
• Adjusted non-GAAP net income per diluted share of $3.78 (previous methodology)

2016 Q4 and Annual earnings